Fosbretabulin and Avastin Combo Delays Progression, But Doubles Hypertension in Ovarian Cancer

Cure Today

Bradley J. Monk, presented findings during at the 2015 Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer.
“Based on the progression-free survival and tolerability of these two anti-vascular therapies, further evaluation is warranted for this chemotherapy-free regimen, with the understanding that fosbretabulin may increase the frequency of hypertension,” said Monk, professor of gynecologic oncology at the University of Arizona Cancer Center. “Overall survival data are currently too early in the timeline to warrant any conclusions....

Bradley J. Monk, presented findings during at the 2015 Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer.

“Based on the progression-free survival and tolerability of these two anti-vascular therapies, further evaluation is warranted for this chemotherapy-free regimen, with the understanding that fosbretabulin may increase the frequency of hypertension,” said Monk, professor of gynecologic oncology at the University of Arizona Cancer Center. “Overall survival data are currently too early in the timeline to warrant any conclusions, because this was a hypothesis-generating trial. But, in general, we now know that vascular disruption is highly significant.” - See more at: http://www.curetoday.com/articles/Fosbretabulin-and-Avastin-Combo-Delays-Progression-But-Doubles-Hypertension-in-Ovarian-Cancer?utm_source=Informz&utm_medium=Cure+Today&utm_campaign=CURExtra%2Demail%2D4%2D8%2D15#sthash.J5MYHZ4C.dpuf